We published an article this morning providing a detailed breakdown of the Sohn Investment Conference presentation made by Social Capital CEO Chamath......
(read more)May 24 - Hedge Funds, News, Stock Analysis, Tech - Comments
Social Capital CEO Chamath Palihapitiya was one of the show-stoppers at the recent Sohn Investment Conference in New York, pitching a Tesla Inc (NASDAQ......
(read more)May 24 - Hedge Funds, News, Stock Analysis, Tech - Comments
International Game Technology Ordinary Shares (NYSE:IGT) scored a very favorable deal with the sale of its Double Down Interactive unit according to commentary......
(read more)May 11 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis, Tech - Comments
William Martin of Raging Capital Management believes TrueCar Inc (NASDAQ:TRUE) investors should pay attention to objects in their investment’s rear......
(read more)May 11 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis - Comments
Lions Gate Entertainment Corp. (USA) (NYSE:LGF) investors can probably point at least some of the blame for Lions Gate’s lackadaisical stock performance......
(read more)May 8 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis - Comments
Billionaire Dan Loeb, the head of $15 billion hedge fund Third Point, has his eyes set on a $20 billion prize. The money manager’s first-quarter......
(read more)May 6 - Activism, Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis - Comments
Warren Buffett of Berkshire Hathaway has been an investing machine for five decades, delivering stunning returns during that time. A mere $1,000 invested......
(read more)May 5 - Hedge Funds, Market Movers, News, Stock Analysis, Tech - Comments
David Einhorn, the billionaire manager of Greenlight Capital doesn’t exactly have a positive image of Tesla Inc (NASDAQ:TSLA) investors, viewing......
(read more)May 5 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis, Tech - Comments
Vilas Capital is probably no stranger to Tesla Inc (NASDAQ:TSLA) investors, as the fund has been an outspoken critic of Tesla in the past, calling it &#......
(read more)May 4 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis, Tech - Comments
Cliffs Natural Resources Inc. (NYSE:CLF) insiders have a history of buying up shares in clusters, the last cluster of which we saw in late-October/early......
(read more)May 4 - Commodities, Insider Trading, Market Movers, News, Stock Analysis - Comments
It’s been a tough run for Glenview Capital, the hedge fund run by billionaire Larry Robbins, which has endured two losing years in a row (an 18.......
(read more)May 3 - Hedge Funds, News, Stock Analysis - Comments
Last week, Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced data from a Phase II study of its lead development asset Anabasum. The data appeared......
(read more)April 4 - News, Stock Analysis - Comments
Introduction The threat of rising interest rates is all the rage in financial circles today. However, the seminal question is: How real is the threat,......
(read more)March 24 - News, Stock Analysis - Comments
The cannabis space has been one of the most closely watched, and the most active, sectors across the last twelve months. The Viridian Cannabis Stock Index......
(read more)March 22 - News, Stock Analysis - Comments
AstraZeneca PLC (ADR) (NYSE:AZN) has acknowledged the receipt of the Complete Response Letter (CRL) from the U.S. Food and Drug Administration for ZS......
(read more)March 21 - News, Stock Analysis - Comments
Nektar Therapeutics (NASDAQ:NKTR) is one of the week’s biggest winners in biotech so far, with the company soaring during the Monday session on the......
(read more)March 21 - News, Stock Analysis - Comments
In an effort to enhance collaboration with Circassia Pharmaceuticals, AstraZeneca PLC (ADR) (NYSE:AZN) has acquired an equity stake valued at $50 million......
(read more)March 20 - News, Stock Analysis - Comments
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has unveiled the authorized generic version of Minastrin, an oral contraceptive that is combined......
(read more)March 20 - News, Stock Analysis - Comments
At the end of last week, Amgen, Inc. (NASDAQ:AMGN) announced some data from its large-scale trial of its cardiovascular risk asset Repatha. The drug first......
(read more)March 20 - News, Stock Analysis - Comments
As you know, I review the list of dividend increases every single week as part of my monitoring process. I usually focus my attention on the ones that......
(read more)March 20 - Dividend Stocks, News, Retirement, Stock Analysis - Comments
Positive results for the Phase III study meant to test the experiences of patients using the eye insert known as Dextenza to relieve pain in a post-surgical......
(read more)March 17 - News, Stock Analysis - Comments
Plans to start a new Phase II study of SER-109, branded ECOSPOR III, have been announced by Seres Therapeutics Inc (NASDAQ:MCRB). The drug is meant to......
(read more)March 17 - News, Stock Analysis - Comments
Target Corporation (NYSE:TGT) operates general merchandise stores in the United States and Canada. Target is a dividend champion, which has paid dividends......
(read more)March 17 - Dividend Stocks, News, Stock Analysis - Comments
Here’s a look at some of the week’s biggest movers in biotech, what’s moving them, and where we expect things to go early next week and beyond.......
(read more)March 17 - Market Movers, News, Stock Analysis - Comments
The Melody Transcatheter Pulmonary Valve that has been developed by Medtronic PLC. Ordinary Shares (NYSE:MDT) has been approved by the U.S. Food and Drug......
(read more)March 17 - News, Stock Analysis - Comments
Reports indicate that there are a number of plaintiffs filing lawsuits against Merck & Co., Inc. (NYSE:MRK) claiming that its shingles vaccine, Zostavax......
(read more)March 16 - News, Stock Analysis - Comments
After recently getting the approval of the U.S. Food and Drug Administration, Novartis AG (ADR) (NYSE:NVS) has announced that a flexible pricing system......
(read more)March 16 - News, Stock Analysis - Comments
Lynparza, an ovarian cancer treatment developed by AstraZeneca PLC (ADR) (NYSE:AZN) has demonstrated its ability to slow down disease progression. AstraZeneca......
(read more)March 16 - News, Stock Analysis - Comments
The head of technical analysis at Oppenheimer (1), Ari Wald, is bullish on Skyworks Solutions Inc (NASDAQ:SWKS). He cites that technology is currently......
(read more)March 16 - News, Stock Analysis, Tech - Comments
After struggling throughout the latter half of 2016 with various development and regulatory pressures, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has......
(read more)March 16 - News, Stock Analysis - Comments
By Pablo Erbar Cellular Biomedicine Group Inc (NASDAQ:CBMG) is a developer of proprietary cell therapies for the treatment of cancer and other degenerative......
(read more)March 16 - News, Stock Analysis - Comments
By Pablo Erbar Last month Vuzix Corporation (NASDAQ:VUZI) disclosed plans to build a pair of custom smart glasses for Toshiba Client Solutions Co. Ltd......
(read more)March 16 - News, Stock Analysis, Tech - Comments
The world’s largest and most-valued semiconductor chip maker, Intel Corporation (NASDAQ:INTC), is about to buy Israeli driverless car technology company......
(read more)March 15 - News, Stock Analysis, Tech - Comments
In the Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) public offering, common shares totaling 22,300,000 will be offered at $6.75 a share. The biopharmaceutical......
(read more)March 15 - News, Stock Analysis - Comments
It’s been a big week for PARP inhibitors. AstraZeneca PLC (ADR) (NYSE:AZN) just put out data from a phase 3 investigation of its lead PARP asset Lynparza......
(read more)March 15 - News, Stock Analysis - Comments
I have owned shares of the largest Canadian Banks as a long-term investment for over four years now. I initiated a position in those five banks in early......
(read more)March 15 - Dividend Stocks, News, Stock Analysis - Comments
In its efforts to contribute to a generation that is tobacco-free, CVS Health Corp (NYSE:CVS) has devoted $50 million for a five-year program. The drug......
(read more)March 14 - News, Stock Analysis - Comments
AstraZeneca plc (ADR) (NYSE:AZN) is reconsidering some of its rejected drugs, as they could possess potential in curing a disease they were not initially......
(read more)March 14 - News, Stock Analysis - Comments
It’s been a busy quarter in the biotechnology space, but it’s not over yet. This month promises to bring with it a flurry of end of quarter catalysts......
(read more)March 14 - News, Stock Analysis - Comments
Pershing Square Capital Management, managed by Bill Ackman, sold its entire stake in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Monday. The investor......
(read more)March 14 - Hedge Funds, News, Stock Analysis - Comments
One of the most compelling markets for investors is the burgeoning legal cannabis industry. With medical marijuana legal in 28 states and recreational......
(read more)March 14 - News, Stock Analysis - Comments
Allergan plc Ordinary Shares (NYSE:AGN) has announced that an application to have new clinical data for Vraylar evaluated has been accepted by the Food......
(read more)March 13 - News, Stock Analysis - Comments
The Centers for Medicare & Medicaid Services (CMS) has granted approval to the Micra Transcatheter pacemaker (Micra TPS) that is manufactured by Medtronic......
(read more)March 13 - News, Stock Analysis - Comments
Every so often, a biotech company takes a hit on some news that seems negative, and at first glance is, but is likely only temporary in terms of impact......
(read more)March 13 - News, Stock Analysis - Comments
Preferred stocks offer the distinction of being unique hybrid instruments with qualities of both stocks and bonds. In that manner, they offer healthy......
(read more)March 13 - ETF Trading, News, Stock Analysis - Comments
Should you add Ladder Capital Corp (NYSE:LADR) to your equity portfolio? There are a lot of metrics to assess a stock’s ‘worthiness’......
(read more)March 13 - Dividend Stocks, News, Stock Analysis - Comments
Should you invest in AT&T Inc. (NYSE:T)? It’s no surprise that the telecom industry has registered a slowdown in recent years. The smartphone......
(read more)March 13 - News, Stock Analysis, Tech - Comments
Colgate-Palmolive Company (NYSE:CL), together with its subsidiaries, manufactures and markets consumer products worldwide. The company operates in two......
(read more)March 13 - Dividend Stocks, News, Stock Analysis - Comments
Caterpillar Inc. (NYSE:CAT) On the Spot Over Tax and Accounting Fraud On March 8, 2017, Caterpillar offices at Peoria, Illinois were raided by federal......
(read more)March 13 - News, Stock Analysis - Comments
This guest post has been written by Mike McNeil, passionate investor, founder of Dividend Stocks Rock and author of The Dividend Guy Blog. The current......
(read more)March 10 - Dividend Stocks, News, Stock Analysis - Comments
